EPS for AVROBIO, Inc. (AVRO) Expected At $-0.54

October 14, 2018 - By Linda Rogers

Analysts expect AVROBIO, Inc. (NASDAQ:AVRO) to report $-0.54 EPS on November, 8.After having $-2.98 EPS previously, AVROBIO, Inc.’s analysts see -81.88 % EPS growth. The stock increased 6.61% or $1.56 during the last trading session, reaching $25.17. About 87,399 shares traded. AVROBIO, Inc. (NASDAQ:AVRO) has 0.00% since October 14, 2017 and is . It has underperformed by 15.62% the S&P500.

AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing ex vivo lentiviral gene therapies to treat rare diseases following a single dose. The company has market cap of $597.08 million. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. It currently has negative earnings. The Company’s lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of fabry disease.

More notable recent AVROBIO, Inc. (NASDAQ:AVRO) news were published by: Seekingalpha.com which released: “AVROBIO builds on successful IPO, up 9%” on September 20, 2018, also Nasdaq.com with their article: “Mid-Day Market Update: Crude Oil Up Over 1%; Akorn Shares Plunge” published on October 01, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on October 10, 2018. More interesting news about AVROBIO, Inc. (NASDAQ:AVRO) were released by: Schaeffersresearch.com and their article: “3 Drug Stocks Getting Crushed” published on October 01, 2018 as well as Nasdaq.com‘s news article titled: “AVROBIO, Inc. to Present at Chardan’s 2nd Annual Genetic Medicines Conference” with publication date: October 04, 2018.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>